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1. INTRODUCTION {#anec12719-sec-0005}
===============

Noncompaction cardiomyopathy (NCCM) is a relatively rare cardiac abnormality with characteristic morphology consisting of a two‐layered myocardial structure with a thin epicardial layer and a noncompacted, thickened endocardial layer with multiple prominent ventricular trabeculations and deep intertrabecular recesses (Jenni, Oechslin, & van der Loo, [2007](#anec12719-bib-0017){ref-type="ref"}). The most commonly affected parts of the left ventricle by this process are inferior and lateral walls from the midcavity to the apex (Jenni, Oechslin, Schneider, Attenhofer Jost, & Kaufmann, [2001](#anec12719-bib-0016){ref-type="ref"}; Stollberger, Gerecke, Finsterer, & Engberding, [2013](#anec12719-bib-0028){ref-type="ref"}). The clinical course of these patients is highly heterogeneous, ranging from asymptomatic, coincidental discovery of the disease at one end of the spectrum to thromboembolic events, heart failure, and even sudden cardiac death (SCD) at the other end (Aras et al., [2006](#anec12719-bib-0005){ref-type="ref"}). Implantable cardioverter--defibrillators (ICDs) have been shown to be highly effective for the prevention of arrhythmic death (Kobza, Jenni, Erne, Oechslin, & Duru, [2008](#anec12719-bib-0020){ref-type="ref"}). Currently, knowledge about risk stratification, arrhythmogenesis, and prognosis is limited. Unfortunately, no reliable indicators of adverse outcomes have been established, and identifying high‐risk patients most likely to benefit from an ICD is still a major clinical challenge.

The lead aVR is an often ignored lead in electrocardiographic (ECG) evaluation, but it may afford unique information as to some clinical settings such as ventricular tachyarrhythmias and left main coronary artery disease (Ducas et al., [2013](#anec12719-bib-0010){ref-type="ref"}; Kireyev, Arkhipov, Zador, Paris, & Boden, [2010](#anec12719-bib-0018){ref-type="ref"}; Vereckei, Duray, Szenasi, Altemose, & Miller, [2008](#anec12719-bib-0031){ref-type="ref"}). A positive T wave in lead aVR (TaVR), as a marker of repolarization abnormality, has been demonstrated to be predictive of the mortality and sudden cardiac death in the general population (Anttila et al., [2011](#anec12719-bib-0004){ref-type="ref"}; Badheka et al., [2013](#anec12719-bib-0007){ref-type="ref"}) as well as in certain cardiovascular disorders including ST‐segment elevation myocardial infarction (STEMI), non‐ST elevation myocardial infarction (NSTEMI), and heart failure (Ayhan et al., [2013](#anec12719-bib-0006){ref-type="ref"}; Icen & Koc, [2017](#anec12719-bib-0014){ref-type="ref"}; Kobayashi, Misumida, Aoi, & Kanei, [2017](#anec12719-bib-0019){ref-type="ref"}; Misumida et al., [2016](#anec12719-bib-0021){ref-type="ref"}; Okuda et al., [2011](#anec12719-bib-0022){ref-type="ref"}; Shinozaki, Tamura, & Kadota, [2011](#anec12719-bib-0025){ref-type="ref"}; Tan, Engel, Myers, Sandri, & Froelicher, [2008](#anec12719-bib-0029){ref-type="ref"}; Tanaka et al., [2017](#anec12719-bib-0030){ref-type="ref"}). However, no data are available as to T‐wave alterations in lead aVR in patients with NCCM. Because the lead aVR sees the apical, lower lateral, and inferior regions of the left ventricle from the opposite side, we hypothesized that the presence of injured myocardium in these regions, as frequently seen in NCCM, would cause to an alteration in lead aVR. Therefore, the aim of this study was to analyze the prevalence of T‐wave alterations in lead aVR and whether T‐wave positivity in lead aVR predicts lethal arrhythmic events or a poor prognosis in patients with NCCM.

2. MATERIAL AND METHODS {#anec12719-sec-0006}
=======================

2.1. Patient population {#anec12719-sec-0007}
-----------------------

We retrospectively analyzed data on 161 consecutive patients (65.8% men, mean age 42.5 ± 15.2 years old) diagnosed with NCCM in our tertiary reference hospital from June 2001 to September 2017. Patients with left bundle branch block, ventricular pacing rhythm, a history of other known coinciding congenital, or acquired heart diseases and patients with significant missing data were not included. Demographic features, electrocardiographic, and echocardiographic parameters of all participants were attained from clinical presentation and examination recordings, clinical follow‐up visits, medical charts of patients, and the electronic databases. This study was conducted according to the principles outlined in the Declaration of Helsinki, and the study protocol was approved by institutional ethics committee of our hospital.

2.2. Echocardiography and NCCM definition {#anec12719-sec-0008}
-----------------------------------------

Patients were being assessed for NCCM with 2‐dimensional and Doppler echocardiographic examinations by experienced echocardiographers. Left ventricular end‐diastolic dimension (LVEDD), end‐systolic dimension (LVESD), and left atrial (LA) diameter were measured. Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson method. The noncompacted to compacted ratio was also assessed. In each patient, NCCM was diagnosed based on the presence of echocardiographic criteria previously described by Jenni et al. ([2001](#anec12719-bib-0016){ref-type="ref"}). These criteria include (a) a characteristic thickened, two‐layered myocardium with a compacted outer and a noncompacted inner layer, the ratio of noncompacted to compacted layer (NC/C) \> 2 measured at end‐systolic phase in parasternal short‐axis view; (b) deep intertrabecular recesses filling with blood from the left ventricular cavity with color Doppler imaging; (c) typical distribution of the noncompacted walls are in the midlateral, midinferior, and apical left ventricle; and (d) absence of coinciding cardiac abnormalities for the isolated form of the disease.

2.3. Evaluation of ECG findings {#anec12719-sec-0009}
-------------------------------

Standard 12‐lead electrocardiograms (ECGs) were performed in a routine fashion in the supine position during quiet respiration and recorded at a paper speed of 25 mm/s and a standardization of 10 mm = 1 mV, in all patients. All ECGs were interpreted by two independent cardiologists who were blinded to all clinical and outcome data. Standard ECG parameters including heart rate, PR interval, QRS duration, QTc duration (Bazett\'s formula), right bundle branch block (RBBB), T‐wave inversion, fragmented QRS (fQRS), J waves, and left ventricular hypertrophy (Sokolow & Lyon, [1947](#anec12719-bib-0026){ref-type="ref"}) were measured. In addition to these conventional ECG parameters, the polarity and amplitude of the T wave in lead aVR were evaluated. The amplitude of T wave in lead aVR was established as the first deflection after the QRS complex and/or maximum deviation from the PR isoelectric line. A positive (upright) T wave was defined as a wave with a dominant upward deflection (˃0 mV) and a negative (nonupright) wave as one with dominant downward deflection (≤0 mV).

2.4. Study endpoints {#anec12719-sec-0010}
--------------------

We described cardiac events as follows: an occurrence of appropriate implantable cardioverter--defibrillator discharge for fast ventricular tachycardia/fibrillation (VT/VF); sustained VT or VF documented with ECG, telemetry monitoring, or Holter recording; SCD (witnessed, unexpected, and instantaneous collapse leading to death from a cardiac cause occurring \<1 hr from symptom onset or within 24 hr of last having been observed in the usual state of health (if unwitnessed)); hospitalization for heart failure; cardiovascular death (SCD, death due to heart failure, and cardioembolic stroke‐related death); and all‐cause death. The follow‐up duration was initiated with the date of his or her first evaluation and ended with the occurrence of death, arrhythmic event, or the date of his or her most recent evaluation.

The primary endpoint of the present study was a composite of lethal arrhythmic events that included SCD, documented VT, or VF or appropriate ICD therapy. Heart failure requiring hospitalization, cardiovascular death, and all‐cause death were also assessed, respectively, as secondary endpoints. Follow‐up for clinical endpoints was performed by review of medical records in our hospital. All interrogated ICD data were checked by cardiologists, who established whether ICD therapies were appropriate. We decided a cardiac event that occurred outside our hospital by direct interviews or phone calls with patients, their relatives, and/or their general practitioners. The cause of death was assessed by evaluating the hospital records, official hospital release forms, or death certificates obtained from National survival registry.

2.5. Statistical analysis {#anec12719-sec-0011}
-------------------------

Statistical analysis was performed using the SPSS statistical software version 23.0 (SPSS, Inc., IL, USA). Continuous variables were reported as mean ± *SD* and median with interquartile ranges as appropriate and categorical variables as frequency and percentage. To test the normality of distribution, Kolmogorov--Smirnov criterion was used. Comparisons of continuous variables between the 2 groups were analyzed with Student\'s *t* test for normally distributed variables and Mann--Whitney U test for variables without normal distribution. Chi‐square or Fisher\'s exact test was utilized to compare categorical variables as appropriate. We first performed a univariate analysis to assess the relation of each variable with the occurrence of primary composite endpoint and all‐cause death, respectively. Variables demonstrating a *p*‐value \< .05 in univariate analysis were entered in multivariate Cox proportional hazards model. Kaplan--Meier curve analysis was used for freedom from arrhythmic events, CV death, all‐cause death, and heart failure requiring hospitalization in patients with or without positive TaVR. Differences between two patients groups were evaluated by use of the log‐rank test. Receiver operating characteristic curve (ROC) analysis was utilized to find the optimum cutoff level for the amplitude of TaVR to predict the lethal arrhythmic events. The cutoff point was established using Youden\'s index. A *p*‐value \< .05 (using a two‐sided test) was considered significant.

3. RESULTS {#anec12719-sec-0012}
==========

From a total of 171 subjects with NCCM, 8 were excluded from this analysis because they had left bundle branch block and ventricular pacing rhythm (making the ECG uninterpretable) and 2 due to missing data in their files. The final study group consisted of 161 patients who fulfilled the inclusion criteria. Patients' baseline clinical, ECG, and echocardiographic characteristics are demonstrated in Table [1](#anec12719-tbl-0001){ref-type="table"}. A total of 10 patients (6.2%) had a family history of SCD, and 5 (3.1%) patients had unexplained syncope. Mean LV ejection fraction was 37.3 ± 13.3. One hundred and thirty‐six (84.4%) patients were in sinus rhythm, whereas the remaining 25 (15.6%) were in atrial fibrillation. Cardiac magnetic resonance imaging (CMRI) was carried out in 34 patients, which further confirmed the diagnosis of NCCM. A total of 79 patients (49.1%) had ICD implantation.

###### 

Baseline clinical, ECG, and echocardiographic characteristics of the study population according to the presence of positive T wave in lead aVR

+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
|                                         | Total             | aVR (+)           | aVR (−)           | *p* Value   |
|                                         |                   |                   |                   |             |
|                                         | *n* = 161         | *n* = 66          | *n* = 95          |             |
+=========================================+===================+===================+===================+=============+
| Age                                     | 42.5 ± 15.2       | 45.4 ± 13.6       | 40.4 ± 10.6       | **0.042**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Male gender, *n* (%)                    | 106 (65.8%)       | 47 (71.2%)        | 59 (62.1%)        | 0.231       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Hypertension, *n* (%)                   | 27 (16.8%)        | 15 (22.7%)        | 2 (12.6%)         | 0.092       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Diabetes, *n* (%)                       | 11 (6.8%)         | 7 (10.6%)         | 4 (4.2%)          | 0.114       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Smoking, *n* (%)                        | 18 (11.2%)        | 7 (10.6%)         | 11 (11.6%)        | 0.847       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| BMI, (kg/m^2^)                          | 24 (21--27)       | 25 (20--28)       | 24 (21--27)       | 0.754       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Coronary artery disease, *n* (%)        | 24 (14.9%)        | 13 (19.7%)        | 11 (11.6%)        | 0.155       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Atrial fibrillation, *n* (%)            | 25 (15.6%)        | 16 (24.6%)        | 9 (9.5%)          | **0.010**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Thromboembolic events, *n* (%)          | 9 (5.6%)          | 7 (10.6%)         | 2 (2.1%)          | **0.021**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| NYHA class III--IV                      | 33 (20.5%)        | 18 (27.3%)        | 15 (15.8%)        | 0.076       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Family history of SCD                   | 10 (6.2%)         | 4 (6.1%)          | 6 (6.3%)          | 0.947       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Syncope, *n* (%)                        | 5 (3.1%)          | 2 (3.0%)          | 3 (3.2%)          | 0.963       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Nonsustained VT, *n* (%)                | 31 (19.3%)        | 16 (24.2%)        | 15 (15.8%)        | 0.181       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Medical treatment                       |                   |                   |                   |             |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| ACE inhibitor or ARB                    | 83 (51.6%)        | 39 (59.1%)        | 44 (46.3%)        | 0.111       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Beta‐blockers                           | 105 (65.2%)       | 48 (72.7%)        | 57 (60.0%)        | 0.095       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Amiodarone                              | 5 (3.1%)          | 2 (3.0%)          | 3 (3.2%)          | 0.963       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Diuretics                               | 51 (31.7%)        | 25 (26.3%)        | 26 (39.4%)        | 0.079       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| LVEDD (mm)                              | 52.0 (46.0--60.0) | 57.5 (49.0--6.24) | 50.0 (46.0--54.0) | **\<0.001** |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| LVESD                                   | 40.0 (34.0--49.0) | 42.0 (38.0--50.0) | 39.0 (26.0--48.0) | **0.007**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| LVEF                                    | 37.3 ± 13.3       | 31.6 ± 10.4       | 41.3 ± 13.7       | **\<0.001** |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| LA diameter (mm)                        | 41.0 (35.0--45.0) | 42.0 (35.7--45.2) | 39.0 (35.0--45.0) | 0.141       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Noncompact/compact ratio                | 3.0 (2.4--3.5)    | 3.1 (2.5--3.6)    | 3.0 (2.4--3.4)    | 0.062       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Heart rate, beats/min                   | 70 (65--74)       | 71.9 ± 12.4       | 69.7 ± 14.2       | 0.762       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| PR interval, ms                         | 168 (136--198)    | 171.2 ± 37.9      | 177.9 ± 37.6      | 0.887       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| QRS duration, ms                        | 108 (97--117)     | 112 (100--118)    | 101 (92--117)     | **0.019**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| QTc interval, ms                        | 435 ± 43          | 447 ± 51          | 427 ± 34          | **0.004**   |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Presence of J wave, *n* (%)             | 39 (24.2%)        | 11 (16.7%)        | 28 (29.5%)        | 0.062       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Fragmented QRS, *n* (%)                 | 85 (52.8%)        | 46 (69.7%)        | 39 (41.1)         | **\<0.001** |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| SV1 + RV5 leads, mV                     | 30.9 ± 13.2       | 33.2 ± 14.2       | 29.3 ± 12.3       | 0.067       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Left anterior fascicular block, *n* (%) | 3 (1.9%)          | 0 (0.0%)          | 3 (2.2%)          | 0.145       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| Complete RBBB, *n* (%)                  | 10 (6.2%)         | 2 (3.0%           | 8 (8.4%)          | 0.163       |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| T‐wave inversion (%)                    | 58 (36.0%)        | 42 (63.5%)        | 16 (16.8%)        | **\<0.001** |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+
| aVR T‐wave amplitude, mV                | −0.2 ± 2.0        | 1.7 ± 1.2         | −1.6 ± 1.0        | **\<0.001** |
+-----------------------------------------+-------------------+-------------------+-------------------+-------------+

Data are presented mean ± *SD*, median with interquartile ranges or *n* (%). Bolded values indicate statistical significance (*p* \< .05).

Abbreviations: ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; LA: Left atrium; LVEDD: left ventricular end‐diastolic diameter; LVEF: left ventricular ejection fraction; NSVT: nonsustained ventricular tachycardia; RBBB: right bundle branch block; SCD: sudden cardiac death.

John Wiley & Sons, Ltd

We then compared patients with NCCM by the presence or absence of positive TaVR (Table [1](#anec12719-tbl-0001){ref-type="table"}). Positive TaVR was found in 66 (41.0%) of all study patients with no difference between both genders. In the positive TaVR group, the patients were older (*p* = .042) and had higher prevalence of atrial fibrillation (*p* = .010). With regard to echocardiographic parameters, patients with positive TaVR had higher LVEDD (*p* \< .001), LVESD (*p* = .007), and lower EF (*p* \< .001) in comparison to patients with negative TaVR. With regard to ECG parameters, patients with positive TaVR had increased width of QTc interval and QRS complex (*p* = .004 and *p* = .019, respectively) and higher prevalence of fragmented QRS (*p* \< .001), as well as negative T waves (*p* \< .001) in comparison to patients with negative TaVR.

During follow‐up over a median (interquartile range \[IQR\]) of 36 (24--60) months, 6 (3.7%) patients died suddenly, 9 (5.6%) received an appropriate ICD therapy for VT/VF, and 7 (4.3%) resuscitated after cardiac arrest for a total of 22 (13.7%) patients with a combined primary endpoint. Table [2](#anec12719-tbl-0002){ref-type="table"} shows the baseline characteristics, ECG, and echocardiographic parameters of the patients with and without the primary combined endpoint. As expected, patients in lethal arrhythmic event group had higher LVEDD (*p* = .004) and lower EF (*p* = .002) in comparison to patients with no event. With regard to ECG parameters, patients with arrhythmic event had increased width of QTc interval, higher prevalence of fragmented QRS, and T‐wave inversion. Similarly, the prevalence of a positive T wave in lead aVR was significantly higher in lethal arrhythmic event group (*p* \< .001).

###### 

Baseline characteristics of the study population according to the presence of lethal arrhythmic events

+-----------------------------------------+-------------------+------------------+-------------+
|                                         | Event (+)         | Event (−)        | *p* Value   |
|                                         |                   |                  |             |
|                                         | *n* = 22          | *n* = 139        |             |
+=========================================+===================+==================+=============+
| Age                                     | 45.1 ± 15.1       | 42.0 ± 15.2      | 0.377       |
+-----------------------------------------+-------------------+------------------+-------------+
| Male gender, *n* (%)                    | 13 (59.1%)        | 93 (66.9%)       | 0.473       |
+-----------------------------------------+-------------------+------------------+-------------+
| Hypertension, *n* (%)                   | 4 (18.2%)         | 23 (16.5%)       | 0.849       |
+-----------------------------------------+-------------------+------------------+-------------+
| Diabetes, *n* (%)                       | 1 (4.5%)          | 10 (7.2%)        | 0.647       |
+-----------------------------------------+-------------------+------------------+-------------+
| Smoking, *n* (%)                        | 4 (18.2%)         | 14 (10.2%)       | 0.262       |
+-----------------------------------------+-------------------+------------------+-------------+
| BMI, (kg/m^2^)                          | 23 (20--26)       | 24 (21--27)      | 0.221       |
+-----------------------------------------+-------------------+------------------+-------------+
| Coronary artery disease, *n* (%)        | 5 (22.7%)         | 19 (13.7%)       | 0.268       |
+-----------------------------------------+-------------------+------------------+-------------+
| Atrial fibrillation, *n* (%)            | 5 (23.8%)         | 20 (14.4%)       | 0.268       |
+-----------------------------------------+-------------------+------------------+-------------+
| Thromboembolic events, *n* (%)          | 3 (13.6%)         | 6 (4.3%)         | 0.077       |
+-----------------------------------------+-------------------+------------------+-------------+
| NYHA class III‐IV                       | 7 (31.8%)         | 26 (18.7%)       | 0.157       |
+-----------------------------------------+-------------------+------------------+-------------+
| Family history of SCD                   | 3 (13.6%)         | 7 (5.0%)         | 0.120       |
+-----------------------------------------+-------------------+------------------+-------------+
| Syncope, *n* (%)                        | 2 (9.1%)          | 3 (2.2%)         | 0.082       |
+-----------------------------------------+-------------------+------------------+-------------+
| Nonsustained VT, *n* (%)                | 7 (31.8%)         | 24 (17.3%)       | 0.108       |
+-----------------------------------------+-------------------+------------------+-------------+
| Medical treatment                       |                   |                  |             |
+-----------------------------------------+-------------------+------------------+-------------+
| ACE inhibitor or ARB                    | 10 (45.5%)        | 73 (52.5%)       | 0.538       |
+-----------------------------------------+-------------------+------------------+-------------+
| Beta‐blockers                           | 17 (77.3%)        | 88 (63.3%)       | 0.201       |
+-----------------------------------------+-------------------+------------------+-------------+
| Amiodarone                              | 1 (4.5%)          | 4 (2.9%)         | 0.675       |
+-----------------------------------------+-------------------+------------------+-------------+
| Diuretics                               | 7 (31.8%)         | 44 (31,7%)       | 0.988       |
+-----------------------------------------+-------------------+------------------+-------------+
| LVEDD (mm)                              | 59.0 (50.0--69.0) | 51.0(46.0--58.0) | **0.004**   |
+-----------------------------------------+-------------------+------------------+-------------+
| LVESD (mm)                              | 40.0 (37.2--57.2) | 40.0(34.0--49.0) | 0.227       |
+-----------------------------------------+-------------------+------------------+-------------+
| LVEF (%)                                | 29.1 ± 12.1       | 38.6 ± 13.1      | **0.002**   |
+-----------------------------------------+-------------------+------------------+-------------+
| LA diameter (mm)                        | 41.0 (37.0--45.5) | 41.0(35.0--45.0) | 0.350       |
+-----------------------------------------+-------------------+------------------+-------------+
| Noncompact/compact ratio                | 3.2 (2.8--3.5)    | 3.0(2.4--3.5)    | 0.128       |
+-----------------------------------------+-------------------+------------------+-------------+
| Heart rate, beats/min                   | 74 (65--80)       | 70 (65--73)      | 0.106       |
+-----------------------------------------+-------------------+------------------+-------------+
| PR interval, ms                         | 169 (131--198)    | 168 (136--198)   | 0.880       |
+-----------------------------------------+-------------------+------------------+-------------+
| QRS duration, ms                        | 118 (104--123)    | 110 (94--117)    | 0.257       |
+-----------------------------------------+-------------------+------------------+-------------+
| QTc interval, ms                        | 467 ± 47          | 430 ± 40         | **\<0.001** |
+-----------------------------------------+-------------------+------------------+-------------+
| Presence of J wave, *n* (%)             | 4 (18.2)          | 35 (25.2)        | 0.477       |
+-----------------------------------------+-------------------+------------------+-------------+
| Fragmented QRS, *n* (%)                 | 16 (72.7%)        | 69 (49.6%)       | **0.044**   |
+-----------------------------------------+-------------------+------------------+-------------+
| SV1 + RV5 leads, mV                     | 32.5 ± 17.5       | 30.6 ± 12.5      | 0.541       |
+-----------------------------------------+-------------------+------------------+-------------+
| Left anterior fascicular block, *n* (%) | 0 (0.0%)          | 3 (2.2%)         | 0.487       |
+-----------------------------------------+-------------------+------------------+-------------+
| Complete RBBB, *n* (%)                  | 0 (0.0%)          | 10 (7.2%)        | 0.194       |
+-----------------------------------------+-------------------+------------------+-------------+
| T‐wave inversion (%)                    | 13 (59.1%)        | 45 (32.4%)       | **0.015**   |
+-----------------------------------------+-------------------+------------------+-------------+
| Positive TaVR, *n* (%)                  | 20 (90.9)         | 46 (33.1)        | **\<0.001** |
+-----------------------------------------+-------------------+------------------+-------------+
| aVR T‐wave amplitude, mV                | 1.4 ± 1.0         | −0.5 ± 2.0       | **\<0.001** |
+-----------------------------------------+-------------------+------------------+-------------+

Data are presented mean ± *SD*, median with interquartile ranges or *n* (%). Bolded values indicate statistical significance (*p* \< .05).

Abbreviations: ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; LA: Left atrium; LVEDD: left ventricular end‐diastolic diameter; LVESD: left ventricular end‐systolic diameter; LVEF: left ventricular ejection fraction; NSVT: nonsustained ventricular tachycardia; RBBB: right bundle branch block.
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Follow‐up data and clinical outcomes were presented in Table [3](#anec12719-tbl-0003){ref-type="table"}. During follow‐up period; cardiovascular death was observed as a secondary endpoint in 12 subjects (7.5%) (sudden death in 6 and death for progressive heart failure in 6), all‐cause mortality was observed as a secondary endpoint in 17 subjects (10.6%), and heart failure requiring hospitalization was observed in 41 subjects (25.5%) among the study population. The presence of positive T wave in lead aVR was significantly associated with both primary and secondary study endpoints.

###### 

Comparison of study endpoints according to the presence of positive T wave in lead aVR

+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Parameter                               | All        | aVR (+), *n* = 66 | aVR (−), *n* = 95 | *p*         |
|                                         |            |                   |                   |             |
|                                         | *n* = 161  |                   |                   |             |
+=========================================+============+===================+===================+=============+
| Lethal arrhythmic events                | 22 (13.7%) | 20 (30.3%)        | 2 (2.1%)          | **\<0.001** |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Sudden cardiac death                    | 6 (3.7%)   | 5 (7.6%)          | 1 (1.1%)          | **0.032**   |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Sustained VF/VT                         | 7 (4.3%)   | 6 (9.1%)          | 1 (%1.1)          | **0.014**   |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Appropriate ICD shock                   | 9 (5.6%)   | 9 (13.6%)         | 0 (0.0%)          | **\<0.001** |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Heart failure requiring hospitalization | 41 (25.5%) | 24 (36.4%)        | 17 (17.9%)        | **0.008**   |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| Cardiovascular death                    | 12 (7.5%)  | 11 (16.7%)        | 1 (1.1%)          | **\<0.001** |
+-----------------------------------------+------------+-------------------+-------------------+-------------+
| All‐cause death                         | 17 (10.6%) | 13 (19.7%)        | 4 (4.2%)          | **0.002**   |
+-----------------------------------------+------------+-------------------+-------------------+-------------+

Bolded values indicate statistical significance (*p* \< .05).

Abbreviations: ICD: implantable cardioverter--defibrillator; VF: ventricular fibrillation; VT: ventricular tachycardia.

John Wiley & Sons, Ltd

In Kaplan--Meier survival analysis, the cumulative incidence of lethal arrhythmic events occurred more frequently in patients with positive compared with negative TaVR (log‐rank, *p* \< .001, Figure [1](#anec12719-fig-0001){ref-type="fig"}). Also, patients with positive TaVR had a higher rate of hospitalization for heart failure, CV death, and all‐cause death compared with patients without positive TaVR (log‐rank, *p* \< .001, *p* \< .001 and *p* = .003, respectively. Figure [2](#anec12719-fig-0002){ref-type="fig"}).

![Kaplan**--**Meier curve analysis of the primary endpoint](ANEC-25-e12719-g001){#anec12719-fig-0001}

![Kaplan**--**Meier curve analysis of the secondary endpoints](ANEC-25-e12719-g002){#anec12719-fig-0002}

The receiver operating characteristic (ROC) analysis explored the discriminatory capability of T‐wave amplitude in lead aVR for primary composite endpoint. Using a cutoff level of 0.1 mV for T‐wave amplitude in lead aVR was determined to be an optimal point in discriminating lethal arrhythmic events (sensitivity 90.9%, specificity 66.9%, area under curve \[AUC\] = 0.791, CI 0.720--0.851; *p* \< .001, Figure [3](#anec12719-fig-0003){ref-type="fig"}). In addition, the negative predictive value to predict primary endpoint was 97.8%.

![Receiver operating characteristic curve of T‐wave amplitude in lead aVR for predicting primary endpoint](ANEC-25-e12719-g003){#anec12719-fig-0003}

Univariate Cox regression analyses showed that, LVEF, LVEDD, duration of QTc interval, T‐wave inversion, and positive T waves in lead aVR were significantly associated with the primary endpoint (Table [4](#anec12719-tbl-0004){ref-type="table"}). However in the multivariate Cox model, positive TaVR (HR: 4.8, 95% CI: 1.2--19.3; *p* = .025) was the only independent predictor of the primary endpoint (Table [4](#anec12719-tbl-0004){ref-type="table"}). In addition, the presence of positive TaVR (hazard ratio 3.5, 95% CI 1.0--12.1, *p* = .045) was also found as an independent predictor of all‐cause mortality (Table [5](#anec12719-tbl-0005){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses for prediction of composite primary endpoint

  Variable                      Univariate analysis   Multivariate analysis                                         
  ----------------------------- --------------------- ----------------------- ------------- ------- --------------- -------
  Age                           1.007                 0.979--1.036            0.639                                 
  Gender                        1.300                 0.554--3.053            0.547                                 
  Hypertension                  1.071                 0.361--3.173            0.902                                 
  Diabetes                      0.488                 0.065--3.679            0.486                                 
  Smoking                       2.226                 0.749--6.617            0.150                                 
  BMI                           0.916                 0.817--1.027            0.135                                 
  Coronary artery disease       1.422                 0.520--3.888            0.493                                 
  Atrial fibrillation           1.251                 0.439--3.562            0.675                                 
  Family history                1.769                 0.513--6.104            0.367                                 
  Syncope,                      3.787                 0.871--16.467           0.076                                 
  Nonsustained VT               1.778                 0.714--4.430            0.217                                 
  NYHA class III--IV            1.914                 0.778--4.706            0.157                                 
  β‐blocker                     1.248                 0.452--3.444            0.669                                 
  ACE inhibitor or ARB          0.590                 0.253--1.376            0.222                                 
  Amiodarone                    2.062                 0.272--15.618           0.484                                 
  LVEF                          0.951                 0.916--0.988            0.010         0.971   0.927--1.016    0.196
  LVESD                         1.016                 0.972--1.062            0.486                                 
  LVEDD (mm)                    1.062                 1.020--1.105            0.003         1.019   0.977--1.063    0.387
  LA diameter (mm)              1.032                 0.969--1.099            0.327                                 
  Noncompact/compact ratio      1.787                 0.810--3.945            0.151                                 
  PR interval                   0.997                 0.983--1.011            0.668                                 
  QRS duration                  1.006                 0.985--1.028            0.576                                 
  QTc duration                  1.010                 1.001--1.019            0.026         1.005   0.995--1.014    0.348
  Presence of J wave            0.840                 0.283--2.498            0.754                                 
  Fragmented QRS                2.140                 0.832--5.503            0.114                                 
  SV1 + RV5 leads, mV           1.015                 0.986--1.045            0.315                                 
  T‐wave inversion              2.922                 1.246--6.854            0.014         1.689   0.617--4.618    0.308
  Positive T wave in lead Avr   9.215                 2.724--31.170           \<0.001       4.856   1.220--19.327   0.025
  aVR T‐wave amplitude          1.448                 1.191--1.759            **\<0.001**                           

Abbreviations: ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; CI: confidence interval; HR: hazard ratio; LA: left atrium; LV: left ventricle; LVEDD: left ventricular end‐diastolic diameter; LVESD: left ventricular end‐systolic diameter; LVEF: left ventricular ejection fraction; RBBB: right bundle branch block; SCD: sudden cardiac death
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###### 

Univariate and multivariate Cox regression analyses for prediction of all‐cause death

  Variable                      Univariate analysis   Multivariate analysis                                       
  ----------------------------- --------------------- ----------------------- ----------- ------- --------------- -----------
  Age                           1.015                 0.982--1.050            0.374                               
  Gender                        0.948                 0.349--2.576            0.917                               
  Hypertension                  1.655                 0.566--4.839            0.358                               
  Diabetes                      1.639                 0.422--6.368            0.475                               
  BMI                           0.938                 0.822--1.070            0.341                               
  Coronary artery disease       1.741                 0.590--5.139            0.315                               
  Atrial fibrillation           1.607                 0.516--5.008            0.413                               
  Family history                1.435                 0.113--9.104            0.342                               
  Syncope,                      1.048                 0.271--11.467           0.647                               
  Nonsustained VT               0.447                 0.099--2.010            0.294                               
  NYHA class III--IV            1.918                 0.654--5.622            0.235                               
  β‐blocker                     2.389                 0.534--10.680           0.254                               
  ACE inhibitor or ARB          1.035                 0.366--2.924            0.948                               
  Amiodarone                    3.120                 0.399--24.394           0.278                               
  LVEF                          0.951                 0.909--0.995            **0.031**   0.955   0.913--0.999    **0.047**
  LVESD                         1.017                 0.966--1.072            0.521                               
  LVEDD (mm)                    1.048                 0.998--1.100            0.060                               
  LA diameter (mm)              1.101                 1.023--1.184            **0.010**   1.071   0.973--1.180    0.162
  Noncompact/compact ratio      1.405                 0.597--3.303            0.436                               
  PR interval                   1.021                 1.002--1.040            0.059                               
  QRS duration                  0.977                 0.946--1.010            0.166                               
  QTc duration                  1.013                 1.003--1.024            **0.009**   1.002   0.991--1.013    0.758
  Presence of J wave            0.271                 0.035--2.071            0.208                               
  Fragmented QRS                0.853                 0.316--2.303            0.754                               
  SV1 + RV5 leads, mV           0.947                 0.906--0.989            **0.014**   0.949   0.909--0.991    **0.018**
  T‐wave inversion              1.815                 0.694--4.744            0.224                               
  Positive T wave in lead aVR   3.440                 1.209--9.788            **0.021**   3.530   1.026--12.145   **0.045**
  aVR T‐wave amplitude          1.364                 1.095--1.699            **0.006**                           

Abbreviations: ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; CI: confidence interval; HR: hazard ratio; LA: left atrium; LV: left ventricle; LVEDD: left ventricular end‐diastolic diameter; LVESD: left ventricular end‐systolic diameter; LVEF: left ventricular ejection fraction; RBBB: right bundle branch block; SCD: sudden cardiac death
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In addition, there was a significant negative correlation between LVEF and T‐wave amplitude in lead aVR (*p* \< .001, Spearman\'s rho = −0.364) and significant positive correlation between LVEDD and T‐wave amplitude in lead aVR (*p* \< .001, Spearman\'s rho = 0.320).

4. DISCUSSION {#anec12719-sec-0013}
=============

This study demonstrated that T‐wave amplitude analysis in lead aVR provides prognostic information for NCCM patients beyond what is available from other well‐known risk factors. The presence of positive TaVR remained a powerful and independent predictor of lethal arrhythmic events and mortality even after adjustment for known risk factors such as LVEF, LV end‐diastolic diameter, and other ECG risk markers. Furthermore, the presence of positive TaVR was significantly associated with all other secondary endpoints, hospitalization for heart failure, and cardiovascular death. To our knowledge, this study is the first of this kind to demonstrate that positive TaVR is a predictor of arrhythmic events and mortality in patients with NCCM.

NCCM has gained increasing attention in routine clinical practice in recent years due to its association with high rates of mortality and morbidity (Jenni et al., [2007](#anec12719-bib-0017){ref-type="ref"}). Importantly, these patients are liable to develop life‐threatening ventricular tachyarrhythmias, which are still among their most frequent causes of death (Jenni et al., [2001](#anec12719-bib-0016){ref-type="ref"}). High‐risk patients can be protected from arrhythmic death by ICD (Kobza et al., [2008](#anec12719-bib-0020){ref-type="ref"}). But, data as to risk stratification of cardiac events are limited owing to the scarcity of the disease. A number of clinical markers that influence prognosis have been described such as left ventricular dilatation, systolic dysfunction, and the extent of ventricular fibrosis (Andreini et al., [2016](#anec12719-bib-0003){ref-type="ref"}; Aras et al., [2006](#anec12719-bib-0005){ref-type="ref"}). However, not all patients at high risk can be identified with these risk factors. The lack of ability to predict prognosis precisely makes clinical decision‐making challenging.

The lead aVR, a commonly neglected lead in rutin clinical practice, has been reported to have a unique diagnostic value in specific clinical settings including left main coronary artery lesions or diagnosis of cardiac arrhythmias (Ducas et al., [2013](#anec12719-bib-0010){ref-type="ref"}; Vereckei et al., [2008](#anec12719-bib-0031){ref-type="ref"}). In recent years, the presence of upright T wave in lead aVR, as a marker of repolarization abnormality, has been demonstrated to be an important predictor of adverse cardiac events in some clinical situations. Anttila et al. (Anttila et al., [2011](#anec12719-bib-0004){ref-type="ref"}) identified the prevalence of positive T wave in lead aVR to be 2.2% in the general population. They showed also the presence of this ECG finding was independently and strongly related with long‐term cardiovascular mortality. In a study with 331 participants with narrow QRS complexes admitted for worsening heart failure, Okuda et al. ([2011](#anec12719-bib-0022){ref-type="ref"}) demonstrated that a more positive T wave in lead aVR was an independent prognostic factor for risk stratification in heart failure patients.

In addition, previous reports have showed that positive TaVR is associated with sudden cardiac death which is possibly caused by ventricular arrhythmic events. A prior data from the Atherosclerosis Risk in Communities (ARIC) study (Rautaharju et al., [2013](#anec12719-bib-0024){ref-type="ref"}) reported a relation between the amplitude of the T wave in lead aVR and cardiovascular mortality, including SCD. In another study, Al‐Zaiti, Fallavollita, Canty, and Carey ([2015](#anec12719-bib-0001){ref-type="ref"}) found that positive TaVR was significantly correlated with reduced EF and SCD presumably caused by major ventricular arrhythmic events. In a meta‐analysis, T‐wave amplitude in lead aVR was proved to be an important prognostic marker for arrhythmic events and SCD in ischemic heart failure patients (Al‐Zaiti, Fallavollita, Wu, Tomita, & Carey, [2014](#anec12719-bib-0002){ref-type="ref"}). In a previous study from our group, we found that in patients with peripartum cardiomyopathy those with positive T waves in lead aVR had higher rates of left ventricular nonrecovery, arrhythmic events and mortality than those with negative T waves in lead aVR (Ekizler et al., [2019](#anec12719-bib-0011){ref-type="ref"}). In another study, Shinozaki et al. ([2011](#anec12719-bib-0025){ref-type="ref"}) evaluated patients with old anterior wall MI who underwent cardiac catheterization and found patients with positive TaVR had lower LV ejection fractions, higher pulmonary arterial pressures, and greater LV end‐diastolic and end‐systolic volumes than those without it. In accordance with previous reports, in our study patients with a positive TaVR had lower LVEF, greater LVEDD and LVESD, and more severely reduced cardiac function. Thus, one may hypothesize that positive T‐wave amplitude in lead aVR may be independently related with pathological LV remodeling.

The exact mechanism linking T wave positivity in lead aVR to the increased risk of cardiovascular mortality and SCD is speculative currently. Lead aVR is the only lead that opposes the direction of the main cardiac vector. All normally positive deflections on the surface ECG will be negative in this lead under normal circumstances (George, Arumugham, & Figueredo, [2010](#anec12719-bib-0013){ref-type="ref"}). The shape of the T wave is established by the spatial‐temporal characteristics of ventricular repolarization, especially the asynchrony of phase 3 of the action potentials. When repolarization of injured myocardial cells is delayed comparing with that of normal cells, the direction of the T‐wave vector alters toward the injured myocardial regions (George et al., [2010](#anec12719-bib-0013){ref-type="ref"}). The lead aVR sees the apical, lower lateral, and inferior regions of the left ventricle from the opposite side. Considering the position of the aVR lead, the presence of injured myocardium (ischemia and/or fibrosis) in the apical, lower lateral, and inferior regions of the left ventricle would make a normally negative T wave to be inverted and manifested as upright T wave in lead aVR (George et al., [2010](#anec12719-bib-0013){ref-type="ref"}). Because NCCM is a myocardial disease process most commonly affects the inferior and lateral walls from the midcavity to the apex of the left ventricle, it would be easily expected that it cause to inversion of T‐wave vector to those injured regions due to the delayed repolarization, thus culminate in a positive T wave in lead aVR.

On the other hand, lead aVR has been neglected until recent years, primarily owing to the misconception that it gives only reciprocal information from the inferolateral and apical regions. It has been assumed that any myocardial injury that would cause T‐wave inversions in the inferolateral leads would be accompanied by a reciprocally positive TaVR (Rautaharju et al., [2009](#anec12719-bib-0023){ref-type="ref"}). This assumption partly explains the high prevalence of T‐wave inversion (63.5%) in our study population with positive TaVR. However, according to our study findings, only positive TaVR revealed a strong and independent relation with primary endpoint in terms of multivariate regression analysis. So, we postulated that positive T‐wave amplitudes in lead aVR were not only mirror images of T‐wave inversions in inferolateral leads, but also a more susceptible marker of myocardial injury and possibly widespread pathological remodeling in cases of NCCM.

The precise substrate for ventricular arrhythmic events in patients with NCCM is not delineated. Nevertheless, it is hypothesized that developmental blockage of conduction and the presence of intratrabecular recesses may create substrates for reentrant circuits (Derval, Jais, O\'Neill, & Haissaguerre, [2009](#anec12719-bib-0009){ref-type="ref"}). Subendocardial ischemia and fibrosis have been demonstrated in NCCM patients anatomically and pathophysiologically. Jenni et al. ([2001](#anec12719-bib-0016){ref-type="ref"}) revealed the histological findings of patients with NCCM showing ischemic lesions and interstitial fibrosis in the endocardium and prominent trabeculae. Previous studies utilizing cardiac MR imaging and scintigraphy with thallium‐201 demonstrated that subendocardial perfusion defects correlate with regions of noncompacted myocardium in NCCM (Finsterer, Stollberger, & Feichtinger, [2002](#anec12719-bib-0012){ref-type="ref"}; Ichida et al., [1999](#anec12719-bib-0015){ref-type="ref"}). In addition, abnormal ion channel activity, cell‐to‐cell coupling, and microvascular dysfunction in the noncompacted myocardial segments were described in patients with NCCM (Steffel et al., [2009](#anec12719-bib-0027){ref-type="ref"}). Furthermore, it is assumed that increased trabeculation with deep intramyocardial recesses moving the Purkinje system deeper into the myocardium (Burke, Mont, Kutys, & Virmani, [2005](#anec12719-bib-0008){ref-type="ref"}). These alterations cause both delayed depolarization and inhomogeneous repolarization. This transmural heterogeneity may culminate in the development of lethal ventricular arrhythmias. The presence of positive TaVR on ECG has been accepted as a marker of repolarization abnormality. The mechanism of its occurence in NCCM has might be explained by this myocardial conduction delay and inhomogeneous repolarization of the ventricles because of myocardial scar and/or ischemia. Therefore, the percentage of positive TaVR (90%) found in this study in NCCM patients with lethal ventricular arrhythmic events could be significant. Interestingly, positive TaVR was also frequently (33%) observed in NCCM patients without ventricular arrhythmic events, possibly reflecting the high rates of repolarization abnormalities seen in NCCM patients.

While we attempt to differentiate between divergent etiologies of cardiac death (sudden vs. related to CHF), it is possible that there is some extent of misclassification. Therefore, we also reported all‐cause death, because it is more objective and less biased than cardiac death. The presence of positive TaVR was also found as an independent predictor of all‐cause death. Increased myocardial ischemia‐/fibrosis‐associated heart failure may be a probable mechanism for elevated mortality rates in patients with positive TaVR. Our findings support this hypothesis that patients with positive TaVR had significantly lower LVEF and higher left ventricular end‐diastolic and end‐systolic diameter than those without it. Importantly, the observed modest correlations of T‐wave amplitudes with LV dysfunction and LV dilatation afford new insights in understanding the complex mechanisms involved in risk stratification using this simple risk marker.

We also studied other ECG findings, and also however, positive TaVR was superior to any other ECG findings in the establishment of patients most at risk for adverse cardiac events. This could be in part because lead aVR may afford sufficient information on a wide range of electrophysiological activities in the almost entirety of the regions which are affected by NCCM. This special feature of TaVR on a simple and widely available surface ECG may enable us to establish high‐risk patients with NCCM.

4.1. LIMITATIONS {#anec12719-sec-0014}
----------------

The present study should be interpreted with some limitations. First, the retrospective observational design may affect the strength of the study. Although one of the largest series of patients with NCCM was investigated, the study population was still limited in size due to the paucity of NCCM. Our study took place in a single tertiary referral center, which may decrease the generalizability of our results to the general NCCM population. We excluded patients with NCCM who had left bundle branch block or ventricular pacing rhythm, which could affect the results. Unfortunately, contrast‐enhanced cardiovascular magnetic resonance which might have helped to improve the understanding of the underlying arrhythmia substrate was not performed at the initial evaluation in all NCCM patients, systematically. Another limitation is that we assessed only initial presenting electrocardiograms, and potential temporal alterations in T‐wave amplitudes were not evaluated in this study. Rather than a causal association, we only showed a relation between positive T waves in lead aVR and adverse cardiac outcomes. Therefore, this study should be noted as hypothesis generating. Prospective and large‐scale studies are necessary to confirm these findings and to clarify the underlying mechanism.

5. CONCLUSION {#anec12719-sec-0015}
=============

This study provides evidence that positive TaVR is associated with increased arrhythmic events, more severe systolic dysfunction, CV death, and all‐cause death in NCCM patients. Beyond the insufficient understanding of the mechanisms, it is worthy of note that a simple subjective assessment of a positive T wave in lead aVR allows the recognition of patients at high risk of adverse CV outcomes. Therefore, we recommend that assessment of T‐wave amplitude in lead aVR should be performed on a routine basis in patients with NCCM given its high sensitivity and negative predictive value for predicting adverse cardiac events. But further confirmatory studies are required before considering positive T wave in lead aVR as a prognostic marker to use in making management decisions in this challenging myocardial disorder.
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